Open AccessSubcutaneous implantable cardioverter defibrillator: Where do we stand?
Author(s) -
Arindam Pande,
Soumya Patra,
Debabrata Bera,
Prakas Chandra Mondal,
Rabin Chakraborty
Publication year - 2016
Publication title -
heart india
Language(s) - English
Resource type - Journals
eISSN - 2321-6638
pISSN - 2321-449X
DOI - 10.4103/2321-449x.183519
Subject(s) - medicine , implantable cardioverter defibrillator , ventricular tachycardia , ventricular fibrillation , intracardiac injection , cardiology , bradycardia , sudden cardiac death , tachycardia , intensive care medicine , heart rate , blood pressure
The indications for implantable cardioverter defibrillators (ICDs) for the prevention of sudden cardiac death (SCD) have rapidly expanded over the past 15 years. Clinical trial data have quickly been implemented into guidelines. The recently introduced subcutaneous implantable cardioverter defibrillator (S-ICD) uses a completely subcutaneous electrode configuration to treat potentially lethal ventricular tachyarrhythmia. The device is now commercially available in India. Clinical trials have proven its effectiveness in detecting and treating ventricular fibrillation (VF) and tachycardia. The S-ICD offers the advantage of eliminating the need for intravenous and intracardiac leads and their associated risks and shortcomings. However, major disadvantages of this device include inability to provide bradycardia rate support and antitachycardia pacing to terminate ventricular tachycardia. As seen with other early examples of evolutionary technology, we hope improvements in design and manufacture will improve some of the drawbacks of the current generation device